Imugene (ASX: IMU) has been granted a trading halt by the ASX pending the release of a strategic alliance announcement, with the company's shares placed in pre-open.
The company has not yet announced any further details on the alliance, with the trading halt to remain in place until the earlier of the announcement - or the commencement of trading on Monday 5 September.
During financial year 2011 Imugene executed an agreement with an international animal health company, to commercialise Imugene's vaccines for pigs and poultry.
The Imugene business model focuses on maximising income from the receipt of research fees, license and royalties.